Kantonsspital St.Gallen

XATOC – Xarelto + Acetylsalicylic Acid

Hans Rickli, Michaela Gemperle & Karin Fink


Treatment patterns and Outcomes across the disease Continuum in
patients with CAD and/or PAD

The study aims to collect real-world data on treatment
patterns and decision points for treatment in patients with
coronary artery disease (CAD) or symptomatic peripheral
artery disease (PAD) treated with rivaroxaban 2.5 mg [twice
a day (BID)] plus low-dose ASA (75-100 mg) [once a day
(OD)] for the prevention of atherothrombotic events in adult
patients at high risk of ischemic events, and to describe the
outcomes under this combination across the broad range of
patient risk profiles encountered in routine clinical practice
type of project clinical studies
status ongoing - follow up
start of project 2020
study design Observational
responsible person Prof. Dr. med. Hans Rickli